S-1/A: Know Labs Eyes $4 Million in Public Offering to Fuel Glucose Monitoring Tech

Know Labs is seeking to raise approximately $4.0 million through a public offering of units, each consisting of one share of common stock and one warrant, to further develop its non-invasive glucose monitoring technology.

Summary

• Know Labs is conducting a firm commitment public offering of 9,259,259 units, each comprising one share of common stock and one warrant to purchase one share of common stock.
• The assumed offering price is $0.432 per unit, potentially generating gross proceeds of approximately $4.0 million.
• Warrants have an exercise price of $0.432 per share and expire five years from issuance.
• The company intends to use the net proceeds for continuing operating expenses and working capital.
• Know Labs is focused on developing and commercializing its proprietary sensor technology for non-invasive medical diagnostics, with an initial focus on blood glucose monitoring.
• The company's technology utilizes radio and microwave spectroscopy paired with AI and ML algorithms.
• Know Labs has announced a KnowU non-invasive wearable continuous glucose monitor working prototype device.
• The company plans to expand its sensor technology to other non-invasive medical diagnostic applications following FDA clearance of its glucose monitoring device.
• Know Labs has identified and is implementing new core workstreams to leverage its intellectual property portfolio of over 300 active patent assets, to generate revenues through patent licensing of opportunities developed in a Skunkworks program.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focusing on factual information about the company and the terms of the offering. While it highlights the potential of the technology, it also acknowledges the risks and challenges involved.

Positives

• The company's technology is non-invasive, using radio waves to identify and measure analytes.
• The sensor technology platform can be integrated into various wearable, mobile, or counter-top form factors.
• The device does not require needles, invasive transmitters, or expensive supplies.
• The prototype sensor collects approximately 1.5 million data points per hour.
• Know Labs is the world intellectual property leader in non-invasive blood glucose monitoring, according to ipCG Capital and PatSnap Research.

Negatives

• There is no established trading market for the units or the warrants.
• The company has a history of operating losses and may not achieve or maintain profitability.
• The company is subject to extensive regulation by the FDA, which could require significant time and costs.
• The company needs additional financing to support its technology development and ongoing operations.
• The company believes that its cash on hand will be sufficient to fund its operations through October 31, 2024.

Risks

• The company might not be able to continue as a going concern.
• The company is still in the early stages of commercialization, refining its technology.
• The company is subject to extensive regulation by FDA, which could restrict the sales and marketing of its products and could cause it to incur significant costs.
• The market price of the company's common stock may fluctuate, and investors could lose all or part of their investment.
• The company may not be able to maintain a listing of its common stock on the NYSE American.
• The warrants are speculative in nature and there is not expected to be an active trading market for the warrants.

Future Outlook

Know Labs plans to expand its sensor technology to other non-invasive medical diagnostic applications following FDA clearance of its non-invasive blood glucose monitoring device and leverage its intellectual property portfolio of over 300 active patent assets, to generate revenues through patent licensing of opportunities developed in a Skunkworks program.

Industry Context

The document positions Know Labs within the competitive landscape of blood glucose monitoring, highlighting its non-invasive approach as a key differentiator against existing continuous glucose monitoring (CGM) systems from companies like Dexcom and Abbott. It also acknowledges competition from other companies developing non-invasive glucose monitors.

Comparison to Industry Standards

• The document mentions Dexcom and Abbott Labs as leading CGM providers, noting their enzymatic determination of blood glucose from interstitial fluid.
• Know Labs aims to compete with these established players by offering a non-invasive solution.
• The document references internal studies comparing Know Labs' sensor technology to the leading continuous glucose monitors from Abbott Labs (Freestyle Libre) and Dexcom (G6).
• The document references an overall Mean Absolute Relative Difference (MARD) of 11.1% in non-invasively measuring blood glucose in participants with prediabetes and Type 2 diabetes using venous blood as a comparative reference.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may benefit from the company's ability to fund its operations and development efforts.
• Customers may benefit from the development of a non-invasive glucose monitoring device.
• Suppliers and creditors may benefit from the company's improved financial stability.

Next Steps

• The company will continue internal and external clinical testing to refine the device.
• Know Labs will pursue FDA clearance for its non-invasive blood glucose monitor.
• The company will explore potential avenues for moving its first product and potential follow-on products into the marketplace.
• Know Labs will continue discussions with potential biopharma, medical device, and consumer electronics partners regarding joint development agreements.

Key Dates

Keywords

glucose monitoring, non-invasive, warrants, public offering, medical diagnostics, Know Labs, common stock, sensor technology, FDA